肝脏 ›› 2016, Vol. 21 ›› Issue (1): 2-5.

• 论著 • 上一篇    下一篇

SF-36量表评价代偿期乙型肝炎肝硬化患者抗病毒治疗对生活质量的改善作用及相关指标分析

魏巍, 殷纪鹏, 李晗, 孔媛媛, 吴晓宁, 周家玲, 孙冬阳, 孙亚朦, 尤红, 贾继东   

  1. 100050 首都医科大学附属北京友谊医院,国家消化系统疾病临床医学研究中心(魏巍,孔媛媛,吴晓宁,周家玲,孙冬阳,孙亚朦,尤红,贾继东); 南京医科大学(殷纪鹏); 美国宾州州立大学(李晗)
  • 收稿日期:2015-09-10 发布日期:2020-06-01
  • 通讯作者: 贾继东,Email:jia Md@263.net
  • 基金资助:
    北京市科委科技计划重大项目(D1211000039120003); 国家科技支撑计划(2015 BAI13 B09)

Assessment of SF-36 scale in life quality of compensated HBV-related cirrhosis patients improved by antiviral therapy and its related indicators

WEI Wei, YIN Ji-peng, LI Han, KONG Yuan-yuan, WU Xiao-ning, ZHOU Jia-ling, SUN Dong-yang, SUN Ya-meng, YOU Hong, JIA Ji-dong   

  1. Clinical Epidemiology and Evidence Based Medicine Center,Beijing Friendship Hospital,Capital Medical University,National Clinical Research Center for Digestive Diseases,Beijing 100050,China
  • Received:2015-09-10 Published:2020-06-01
  • Contact: JIAJi-dong,Email:jiamd@263.net

摘要: 目的 采用SF-36量表评价代偿期乙型肝炎肝硬化患者应用不同治疗策略,其生活质量改善情况及其相关影响因素分析。方法 入组405例代偿期乙型肝炎肝硬化患者,根据病情和经济状况选择单药组(ETV0.5 Mg,1次/d)和联合用药组(ADV10 Mg,LAM100 Mg,1次/d),治疗104周,随访的同时记录患者HBVDNA、Fibroscan、ALT和AST等指标,应用SF-36量表评价患者的生活质量。结果 治疗104周时,患者生存质量有改善(F=10.78,P<0.01),并且改善情况与基线的HBVDNA(r=-0.647,P=0.030)、Fibroscan(r=-0.485,P=0.047)、ALT/AST(r=-0.356,P=0.022)相关。结论 对于代偿期乙型肝炎肝硬化患者,不同抗病毒治疗方式可改善患者生活质量,并且生活质量的改善与一些反映抗病毒效果的指标相关。

关键词: 代偿期乙型肝炎肝硬化, SF-36量表, 抗病毒治疗

Abstract: Objective To investigate feasibility of SF-36 scale in assessing the life quality of compensated hepatitis Bvirus(HBV)-related cirrhosis patients im proved by different anti-viral strategies and its related indicators.Methods Atotal of 405 compensated HBV-related cirrhosis patients were divided into Monotherapy group(entecavir 0.5 Mg,qd)and combination group(adefovir 10 Mg,lamivudine 100 Mg,qd)according to their healthy condition and financial status. During 104 weeks of treatment,HBVDNAload,Fibroscan,levels of alanine aminotransferase(ALT),aspartate transaminase(AST)and other related indicators were recorded,and SF-36 scale was performed to assess patients'life quality. Results At the end of follow-up,life quality of these patients was im proved(F=10.78,P<0.01),which was related to HBVDNAload(r=-0.647,P=0.030),Fibroscan(r=-0.485,P=0.047)and ALT/ AST(r=-0.356,P=0.022)at baseline. Conclusion Different antiviral treatments could im prove life quality of compensated HBV-related cirrhosis patients,which is related to so me antiviralindicators.

Key words: compensated HBV-related cirrhosis, SF-36, Antiviral therapy